Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

• Company develops pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists
  • Initiated Phase 1 clinical trial with ORX750 in development for sleep-wake disorders; Safety and efficacy data in acute sleep deprivation in healthy volunteers assessed using the Maintenance of Wakefulness Test (MWT) on track for 2H 2024
  • ORX142 Nominated as Development Candidate; Currently Engaging in IND Facilitating Activities for Selected Neurological, Neurodegenerative and Psychiatric Disorders with Excessive Daytime Sleepiness (EDS)
• SerpinPC registration program for the treatment of hemophilia B in development; PRESent-2 Part 1 interim analysis planned for 2024

BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines with transformative impact for patients, today reported financial results and business highlights for the second quarter ended June 30, 2024.

“Momentum is building in Centessa’s orexin agonist program. In the second quarter, we initiated a Phase 1 clinical trial with ORX750, a potential best-in-class OX2R agonist being developed for sleep-wake disorders, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Today, we are rapidly approaching a potentially transformative milestone with safety and efficacy data in acute sleep deprivation in healthy volunteers assessed using the MWT, an established registrational and objective endpoint for EDS in sleep-wake disorders, on track for the second half of this year,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “Given that healthy volunteers have normal orexin tone, data from this study have the potential to enable dose selection for planned clinical studies of ORX750 in subjects with NT1, NT2 and IH. The data also have the potential to open the door to evaluating our growing pipeline of orexin agonists in clinical studies for a range of conditions in which EDS is a significant burden. We are working to advance our pipeline to address these additional areas of high unmet need, and are pleased to announce ORX142, an orally administered, highly potent and selective OX2R agonist, as our development candidate for potential indication expansion into select neurological, neurodegenerative and psychiatric conditions with EDS. ORX142 is currently in IND enablement activities and we look forward to sharing preclinical data in the near term.”